Biodesix (BDSX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 35% year-over-year to $18.2 million, driven by strong lung diagnostics adoption and robust reimbursement, despite weather-related disruptions and slower sales team expansion.

• Lung diagnostic revenue grew 40% to $17.2 million, while biopharma services revenue declined 17% to $1.0 million due to project timing.

• Gross margin rose to 77.0% from 76.1% a year ago, reflecting operational efficiencies and higher test volumes.

• Net loss improved 6% year-over-year to $10.3 million, with continued focus on cost discipline and path to profitability.

• Cash and cash equivalents stood at $31.4 million as of September 30, 2024, after making a final $6.1 million milestone payment for the Integrated Diagnostics acquisition.

Financial highlights

• Q3 2024 total revenue was $18.2 million, up 35% year-over-year; nine-month revenue rose 48% to $50.9 million.

• Lung diagnostic testing revenue grew 40% to $17.2 million on 13,900 tests (34% volume growth).

• Biopharma services revenue declined 17% to $1.0 million due to project timing, but backlog reached a record $11.1 million.

• Gross profit was $14.0 million, with a 77.0% margin, up from 76.1% in the prior year period.

• Operating expenses (excluding direct costs) increased 29% year-over-year in Q3, mainly due to higher sales, marketing, and depreciation from new facilities.

Outlook and guidance

• Reaffirmed 2024 revenue guidance of $70–$72 million.

• Adjusted EBITDA profitability expected in the second half of 2025.

• Anticipate sequential growth in lung test volumes and biopharma revenue in Q4, with no long-term impact from hurricane disruptions.

• Plan to add 6–8 sales team members per quarter in 2025 to support growth.

• Management expects continued operating losses in the near term as investments in growth and innovation persist.